-First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community- -Commenced exclusive distribution of SIVEXTRO in the U.S. on April 12, 2021 and moving forward will record 100% of net product
DUBLIN, Ireland , May 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
DUBLIN, Ireland , April 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial
- SIVEXTRO now available under Nabriva’s National Drug Code - 100% of SIVEXTRO’s net product sales to be recorded by Nabriva DUBLIN, Ireland and FORT WASHINGTON, Pa. , April 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the
DUBLIN, Ireland , April 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder ,
March 24 at 8:00 AM EDT WEP Clinical (WEP) and Nabriva Therapeutics (Nabriva) are pleased to announce the expansion of the XENLETA® (lefamulin) Named Patient Program (NPP) into Australia, New Zealand, Singapore and South Africa. NPP is designed to ensure that physicians can request IV or oral
-Post Hoc analysis published in The Journal of Emergency Medicine demonstrates patients with moderate to severe CABP can be managed effectively as outpatients with a 5-day, monotherapy regimen of oral XENLETA DUBLIN, Ireland , March 16, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:
-Relaunched XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community with 60 sales representatives- -Nabriva plans to initiate a Phase 1 clinical trial of XENLETA in patients with cystic fibrosis- -Conference call today at 4:30 p.m.
DUBLIN, Ireland , March 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full
